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Organoid culture faithfully reproduces in vitro the in vivo characteristics of the intestinal/colon 
epithelium and elucidates molecular mechanisms underlying the regulation of stem cell 
compartment that, if altered, may lead tumourigenesis. CRISPR-Cas9 based editing technology 
has provided promising opportunities for targeted loss-of-function mutations at chosen sites in 
the genome of eukaryotes. Herein, we demonstrate a CRISPR/Cas9-mediated mutagenesis-
based screening method using murine intestinal organoids by investigating the phenotypical 
morphology of cas9-expressing murine intestinal organoids. Murine intestinal crypts can be 
isolated and seeded into Matrigel and grown into stable organoid lines. Organoids subsequently 
transduced and selected to generate Cas9 expressing organoids. These organoids can be further 
transduced with the second lentiviruses expressing guide RNA (gRNA) (s) and screened for 8-
10 days using bright-field and fluorescent microscopy to determine possible morphological or 
phenotypical abnormalities. Via phenotypical screening analysis, the candidate knockouts can 
be selected based on differential abnormal growth pattern vs their un-transduced or lenti-GFP 
transduced controls. Further assessment of these knockout organoids can be done via Phalloidin 
and Propidium iodide (PI) staining, proliferation assay and qRT-PCR and also Biochemical 
analysis. This CRISPR/Cas9 organoid mutagenesis-based screening method provides a reliable 
and rapid approach for investigating large numbers of genes with unknown/poorly identified 
biological functions. Knockout intestinal organoids can be associated with the key biological 
function of the gene(s) in development, homeostasis, disease progression, tumorigenesis and 





Colorectal Cancer is the third most common cancer worldwide with approximately 1.1 million 
new diagnoses (6.1% of all cancers) in 2018 [1]. Regrettably, variations in treatment response 
and subsequent survival rates may be caused by significant heterogeneity of CRC tumours [2]. 
This variance makes the modelling of CRC in the laboratory challenging, with traditional 2D 
immortalised cell models limited by their inherent simplicity and genetic drift, reducing 
reproducibility and validity across functional genetics and drug response studies, while full in 
vivo models are vastly expensive and resource intensive, making them impractical for the 
majority of research centres. Therefore, studying of CRC and other cancers requires novel 
methods to be developed that facilitate more accurate investigations without the resource 
requirements of full in vivo modelling.  
One of the most recent and promising modelling systems to be introduced is organoids: a 3D 
(3-dimentional), multicellular culture that mimics the phenotype of their original tissue and are 
compatible with many standard laboratory protocols. Stem cells from the organ in question are 
cultured with appropriate growth factors resulting in a small “organ in a dish” that can be 
maintained and expanded almost indefinitely. Organoids faithfully reproduce functional 
genetic or pharmacological changes visible in their originating organ, and have been cultured 
from the brain [3], retina [4], stomach [5], lung [6] and small intestine [7,8] among others from 
both human patients and mice, providing a crucial “middle ground” alternative between 
immortal cell culture and full in vivo animal models for functional generic analysis, high 
throughput drug testing [9], biobanking [10], tumour microenvironment [11], disease 
modelling [12,13] and targeted gene editing [14] via CRISPR/Cas9 technology, validating data 
between experimental models. When generated from both adjacent normal and matched 
tumour samples of an individual patient, epithelial organoids can provide an excellent tool for 
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researchers to investigate a wide range of cellular and molecular events directly related to 
individual patient care.  
The CRISPR/Cas9 gene editing system provides a robust tool for generating genetically 
modified in vitro models. With recent systems capable of both “knock-in” and “knock-out” of 
chosen genes, CRISPR/Cas9 is used for generating in vitro cellular models for study. CRISPR 
editing has been successfully applied to cultured human organoids [15], demonstrating both an 
ideal platform and tool for assessing functioning of individual genes in multiple tissue types 
without the limitations and ethical implications of generating full in vivo models. 
Matano et al. introduced CRISPR/Cas9-mediated sequential mutations in organoids derived 
from the normal human intestinal epithelium [16]. They demonstrated that engineered 
organoids harbouring mutations at driver genes including APC, SMAD4 and TP53 KRAS 
and/or PIK3CA grew independent of niche factors similar to the tumour counterparts and 
developed tumours upon transplantation kidney subcapsule in mice. These results highlighted 
the significance of morphological alterations in organoids. Inconsistent with the previous 
study, Drost and colleagues also utilized the CRISPR/Cas9 to engineer intestinal organoids 
mutated for APC, KRAS, TP53 and SMAD4. They revealed that simultaneous inactivation of 
APC and P53 drive the extensive aneuploidy, the main feature of tumour progression [17]. In 
another study, CRISPR/Cas9 mediated engineering of intestinal organoids in cystic fibrosis 
patients was successfully applied to repair the deletion at position 508 of cystic fibrosis 
transmembrane conductor receptor (CFTR) [18]. These studies have used CRISPR/Cas9 
expression in organoids, but protein expression and success rate have varied considerably. 
Given the fragility of organoid cultures, electroporation and other invasive methods are 
unlikely to produce sufficient qualities for larger projects. 
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Herein, we present a method for isolating and culturing mouse intestinal crypts and culturing 
organoids, establishing Cas9 protein expression via lentiviral transduction, and subsequently 
using viral transduction of targeted Cas9 plasmids to generate genetic knockout organoid lines 
suitable for functional exploration via phenotypical or biochemical analysis. We propose that 
this CRISPR/Cas9-mediated mutagenesis-based screening method can provide a promising 
approach which facilitates the rapid and reliable identification and selection of new genes play 






2.1 Mouse intestinal organoid isolation 
1. HA-Rspo1-Fc cells: received from Prof. Hans Clevers laboratory. 
2. Mice: C57BL/6J mice, approximately 4-6 weeks old were used. Mice were housed and 
bred in the transgenic animal facility of the Biomedical Service Unit at the University of 
Nottingham. 
3. Fresh organoid medium: basal Advanced DMEM/F-12 medium, 2 mM L-glutamine, 100 
U/ml Penicillin/Streptomycin and 10 mM HEPES was supplemented with N2 supplement 
(1x), B27 supplement (1x), 1 mM N-acetylcysteine to stimulate cell proliferation, 50 
ng/mL murine recombinant epidermal growth factor (mEGF) to activate EGF signaling 
pathway, 1μg/mL R-spondin 1 (in-house) as Wnt agonist and 100 ng/mL Noggin (in-
house) to inhibit BMP pathway.  




2.2 Lentivirus Production, transduction and generation of stable organoid lines, 
protein and RNA extraction and Phalloidin staining.  
1. Human HEK-293 (viral production cells). 







7. Penicilin/Streptomycin (P/S). 
8. Opti-MEM. 
9. Polyethylenimine (PEI). 
10. Polybrene Reagent. 
11. Fluorescent microscopy system. 
12. Phalloidin. 
13. DAPI mounting medium. 
14. 8 µg/ml polybrene. 
15. Paraformaldehyde. 
16. Triton X-100. 
17. Virus sucrose solution 50 mL in ultrapure water: 10% sucrose, 50 mM Tris HCL pH 7.4, 
100 mM NaCL, 0.5 mM EDTA.  
18. RIPA buffer [Radioimmunoprecipitation assay buffer (RIPA buffer; 150 mM sodium 
chloride, 1% NP-40 and 1% sodium dodecyl sulphate) containing 1x protease inhibitor 
cocktail]. 
19. TRIzol (TRI reagent). 







The brief step-by-step flowchart and a diagram of generating knockout intestinal organoids 
using the lentivirus-based system for Cas9/gRNA expression and subsequent analysis have 
summarised in Figures 1 and 2. 
3.1 Mouse intestinal organoid isolation 
1. Sacrifice the mouse and excise the whole intestine from the abdominal cavity.  
2. Clean the specimen carefully with ice-cold PBS to eliminate external connective tissues 
and internal faeces (see Note 1).  
3. Cut a section from duodenum, jejunum and ileum and open longitudinally.  
4. To detach the villi, subdivide every piece in small fragments of approximately 1mm and 
wash with cold PBS several times, into a 50 mL falcon tube.  
5. Once the PBS become clear, incubate the intestinal pieces with 3 mM EDTA in PBS for 45 
min at 4 °C to separate the crypts by chelation.  
6. Transfer the fragments to a falcon containing 10% FBS/PBS and agitate frequently and 
subsequently filter through a 70 μm strainer.  
7. Following the filtration, collect the crypt fragments on top of the strainer and transfer to a 
new falcon containing 10% FBS/PBS. 
8. Agitate and pass through the filter (this process repeated 3-4 times). 
9. Evaluate the filtered medium by using an inverted microscope in order to choose the best 
fraction in term of purity and crypt concentration [8,21].  
10. Centrifuge crypts at 300 xg for 5 min. Remove the supernatant carefully after the 
centrifugation step and re-suspend crypts in ice-cold Matrigel.  
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11. Add 25 μL of crypts-containing Matrigel in pre-warmed 48-well plate. Next, transfer the 
plate to a 37 °C, 5% CO2 incubator for approximately 10 minutes to allow Matrigel to 
solidify.  
12. After 5-10 min in 37 °C incubator, distribute 300 μL of fresh organoid medium into each 
well to cover the Matrigel drop. Culture the crypts into 37 °C, 5% CO2 incubator and 
replace the organoid medium every 48 h. Monitor regularly organoid growth by inverted 
BF microscopy (see Note 1). 
3.2 Lentivirus Production  
1. Seed HEK293-T cells in a total of 10 mL DMEM per 75 cm2 flask. Keep the density of 
cells around 70-80% at the day of transfection (no greater than 90%) (see Note 2). 
2. Agitate plate crossways to spread cells evenly. Incubate overnight at 37 C. 
Day 1 
3. Calculate volumes required for plasmid transfection and PEI (final volume per plate 15 μg 
LV construct, 5 μg pMDG2 packaging, 10 μg pCMV R8.74 packaging plasmid, 1.5 mL 
Opti-MEM per 75 mL flask) (see Note 3). 
4. Add 1.5 mL Opti-MEM to a 15 mL tube per each flask to be transfected.  
5. Add the required amount of packaging and transgene plasmids (no4) to the tube per each 
flask to be transfected. 
6. Prepare the PEI concentration (3-4 µL/1 µg plasmid DNA). 
7. Incubate for 5 min at room temperature. 
8. Add the PEI to each tube containing the plasmid DNA (see Note 4). 
9. Incubate the mixture for 20 min at room temperature. 
10. Add the Opti-MEM/plasmid (packaging plasmid and PEI) gently to flask, leave the flasks 
for 6-9 h. Gently agitate every 2 h for best results. 
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11. Check cells after 6 h, and then change with complete DMEM medium. Incubate overnight 
37 C. 
Day 2-3 
12. If gRNA has fluorescent reporter gene, check transduction efficiency. Transfer supernatant 
from flasks into 50 mL falcon tube and filter through 45 µm filter unit (see Notes 5 and 6). 
13. Replace the medium with complete DMEM medium (3 flasks at a time) and incubate for a 
further 24 h. 
14. Store virus-containing medium at 4 degrees. (cover tubes with parafilm. Please note that 
these samples are highly dangerous and should be securely stored). 
Day 4 
15. Repeat virus harvest to have 3 days of collection [aprox 60 mL of virus containing medium 
per plasmid]. Mark samples with day of collection. The titre usually declines with each 
day.  Some detachment of cells may also occur. 
16. Pipette into ultracentrifuge tubes containing 1 mL of virus sucrose solution (20%), ~7-8 
mL viral supernatant per tube, ensure equal volumes to balance. 
17. Ultracentrifuge at 10,000 rpm for 4 h at 4 C. 
18. Discard supernatant by careful pipetting into beaker of Virkon. Carefully aspirate walls of 
tube to dry, without touching bottom/pellet (pellet may be invisible, and care must be taken 
not to disturb). 
19. Optional: allow tube to air dry under hood for 10-15 min to maximise supernatant removed. 
20. Add 500 uL of organoid medium or complete ADMEM to each tube.  Leave the tubes 
overnight at 4 C. 
21. Take dry ice. Transfer all virus into one tube, pipette several times before transfer to 
disaggregate the virus particles. Try to avoid bubbles as they reduce useful volume. 
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22. Aliquot 50-60 uL into Eppendorf’s. Transport on dry ice and store at -80 C. Try not to 
freeze/thaw virus aliquots several times as transduction efficiency is reduced with each 
cycle (see Notes 3). 
3.3 Transduction and generation of stable organoid lines  
1. Passage the organoids into sufficient number of wells prior LV transduction [typically 10 
confluent organoids per well, 3-4 wells per transduction]. Culture the organoids in Wnt3a 
supplement to form hyper proliferative structures. 
2. Break the basement matrix containing the mature organoids with 1 mL pipette in chilled  
PBS. 
3. Transfer the fragments into a 15 mL tube. 
4. Centrifuge, 3 min for 300 xg. 
5. Aspirate the PBS and the basement matrix residue as much as it is possible and keep the 
pellet. Pellet may be completely invisible. 
6. Repeat step 2-6 twice more. 
7. Re-suspend the pellet with PBS (300 µL) and break down the fragments with 200 mL 
pipette (20-30X). 
8. Centrifuge, 3 min for 300 xg. 
9. Make up medium containing polybrene to working concentration 16 µg/mL (final 8 
µg/mL). 
10. Re-suspend the pellet with the high titre LV and polybrene and leave the mixture for 4 h in 
37-degree incubator (see Note 5). 
11. Agitate the virus containing the organoid fragments every 30 min, using the 200 µL pipette 
to maximize the transduction efficacy. 
12.  After 4 h, centrifuge the transduced organoids for 3 min for 300 xg. 
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13.  Discard the supernatant and add required amount of basement matrix and mix the pellet 
gently using a 200 µL pipette. 
14. Seed the organoids (25 µL) in each well of 48 well plate. 
15. Incubate the organoids in incubator for 5 min and add the complete organoid medium as 
described. 
16. Start the selection process for the generation of the stable organoid lines from 48 h post 
transduction. (G418: 200 µg/uL, puromycin: 1 µg/uL). 
17. Continue the selection process until the negative control (un-transduced organoids are 
completely dead). 
18. Passage the resistant (survived), stable (transduced) organoids and continue antibiotic 
selection. 
19. After 2nd round of the selection, expand the organoids in free-antibiotic medium (see Notes 
7-11). 
20. Freeze organoids. Transport on dry ice and store at -80 C. The cryopreservation of 
organoids enables the freezing of knockout organoid lines post-screening (see Note 12). 
21. Validation and exploration the selected organoid line via RT-PCR, WB and Phalloidin 
staining (see protocols 3.4, 3.5 and 3.6). 
  
3.4 Organoid protein extraction  
1. Western blot validation requires sufficient number of organoids (at least 6 wells of 20-30 
mature organoids/well). 
2. When the organoids are grown after 6-9 days, follow the steps 1-8 of transduction protocol. 
3. Re-suspend and incubate the organoids pellet in 70-80 µl of RIPA buffer for 20 min in cold 
room, while rocking. 
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4. Lyse and homogenise the organoids using a syringe (microlance) occasionally within the 
incubation time. 
5. The lysate can be used directly for the western blot analysis. 
3.5 Organoid RNA extraction  
1. Extract total RNA from organoids using TRI reagent according to the manufacturer’s 
instructions.  
2. To remove the Matrigel, incubate organoids with Matrigel cell recovery solution for 3 h at 
4 °C. 
3. Wash with PBS twice. 
4. Centrifuge into microcentrifuge tubes.  
5. Homogenise organoid pellet manually with 500 µL of TRI reagent and incubate for 5 min 
at RT. To maximize the homogenising, the organoids can be agitated using a 200 µL pipette 
every 1 min.  
6. Add 100 µL of chloroform per 500 µL of TRI reagent to the samples and incubate for 3 min 
at RT. Mix vigorously; then, centrifuge the samples at 12,000 xg at 4 °C for 15 min to 
separate RNA (aqueous phase). 
7. Transfer the upper phase containing RNA to a fresh tube and mix with 250 µL of 
isopropanol per 500 µL of Trizol. After 10 min at RT, precipitate RNA at 12,000 xg for 10 
min at 4 °C (see Note 13). 
8. Wash the pellet two times with cold 75% ethanol by centrifugation at 7,400 xg for 8 min at 
4 °C, air dried and re-suspend with 20 µL of DNase/RNase free water.  
9. Measure RNA concentration by Nanodrop and store the samples at -80 °C. 
 
3.6 Phalloidin staining of organoid culture 
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1. Select 5-6 wells of confluent organoids and add 500 µL of 4% PFA for fixation. Incubate 
the organoids in 4 °C for 1 h. 
2. Discard the PFA gently, collect the organoids in a tube (15 mL falcon) and wash the 
organoids with PBS. Then centrifuge for 3 min, 300 xg.  
3. Repeat this step twice. 
4. Discard the PBS and permeabilize the organoids with 500 µL of 0.5% Trtiton X 100 for 30 
min at RT. 
5. Wash twice with PBS, 5 min. 
6. Add 800 µl in each tube with Phalloidin 1:500 diluted, keep in darkness and incubate for 40 
min at RT. 
7. Wash twice with PBS, 10 min. 
8. Discard the PBS and lay out the organoids in the microscopy slide.  
9. Mounting with DAPI.  
4. Notes 
1. Intestinal organoids provide an excellent in vitro model to investigate the molecular 
mechanisms of CRC. Our experience indicates that initial isolation of can produce between 
8-12 wells of 10-20 organoids per well. Initial isolation will also produce a significant 
amount of extraneous debris that can be cleared during the first and second post—isolation 
subcultures. Not all organoids will successfully proliferate/differentiate and will die during 
this initial stage. Each well of 10-12 organoids can generally be subcultured 1:3 with 
minimal loss. Over-seeding organoids will cause starvation and loss during the growth 
period, while under-seeding can lead to reduced subculture efficiency. 
2. The HEK293T cells should be healthy, of low passage number and in the exponential phase 
of growth. Make sure they are passaged regularly and do not allow to reach confluence. 
15 
 
3. Do not add antibiotics to virus harvesting medium and try not to freeze/thaw virus aliquots 
several times as transduction efficiency is reduced with each cycle. 
4. For the transfection, polyfectamine and other related reagents can be used instead. 
5. We found viral transduction efficiency was very poor when initial plasmid transfection was 
lower than 50%. Reducing viral dilution post-titration may improve efficiency if gRNA has 
low transfection rate. 
6. Please ensure that your Cas9 plasmid selection marker is different to that in your 
prospective plasmids. 
7. Organoid morphology is not exact and large number of images is necessary to quantify any 
potential changes based on knockout. 
8. In the present study, monitoring the phenotypical alterations of knockout organoids vs 
controls enabled the analysis and selection of candidate genes mediated by the abnormal 
morphology. Of note, not all the proteins of interest are expressed in intestinal organoids 
and some may not show a significant phenotypical change due to non-essential functions 
or functional compensation by their paralogues. 
9. As far as we are aware, this is the first study to utilise organoids for large scale screening 
of a targeted group of genes using stable and abundant Cas9 expressing organoids. While 
several studies have been published on the uses of organoids in cancer studies [22,23], drug 
resistance [24], the use of engineered organoids has been limited up to this point.  
10. Organoids represent a new opportunity and hope for both biomedical research and 
personalised, regenerative medicine, particularly for the generation and transplant of 
patient-derived tissue that will prevent rejection and immune responses. However, current 
organoid methodology is still limited in both size and practicality, with the lack of 
vasculature limiting the maximum size of organoid models before necrosis occurs in the 
central cells due to lack of growth factors, and extracellular matrix materials such as 
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Matrigel will break down if samples expand greatly. One recent paper by Grebenyuk & 
Ranga [25] discussed combining multiple organoid types in the same dish to potentially 
produce hybrid tissue samples that could grow too much greater sizes due to 
vascularisation, possibly removing that limitation. While organoids have been 
demonstrated to self-assemble into ad-hoc structures roughly analogous to their source 
anatomy [26], they are currently unsuitable to such delicate physical engineering.  
11. With CRISPR/Cas9 producing accurate mutations and organoids faithfully representing 
their origin tissues, it is now possible to model how individual genes may affect multiple 
tissue types or explore how a specific tissue type is affected by knockout without the cost 
and ethical considerations of in vivo alternatives. This method demonstrates generating 
CRISPR/Cas9 organoids and subsequent knockout organoid lines, representing a 
significant step forward in reducing and replacing the use of animal models in research. 
While organoids will not completely replace animal models in research, they provide both 
a middle ground option and triage method for future research. 
12. This provides the opportunity to rapidly expand organoid use across research groups, 
collaborations and bioscience by allowing collaborative researchers to share engineered 
organoids, and the production of an “organoid bank” in a similar way to standard cell lines. 
13. Incubation of the organoid lysate in isopropanol step overnight can be done to increase 
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